Treatment and Outcomes for MA and FFS Patients with Diabetes

  • This page as PDF

Summary

Avalere released a white paper comparing detection, treatment, outcomes, and spending between MA and FFS Medicare for patients with type 2 diabetes.

In the white paper, Avalere compared outcomes for Medicare Advantage (MA) and fee-for-service (FFS) patients with type 2 diabetes at three distinct disease phases: prediabetes, incident diabetes (patients at first type 2 diabetes diagnosis), and chronic diabetes (patient has had type 2 diabetes for more than a year). We found that:

  • MA patients with prediabetes who later developed type 2 diabetes received their type 2 diagnosis earlier (relative to the date of the prediabetes diagnosis) than FFS patients.
  • MA patients with incident diabetes were more likely than FFS to fill prescriptions for medications to treat diabetes and related conditions within the first year of diagnosis.
  • While similar rates of primary care provider visits occurred between MA and FFS patients with chronic diabetes, MA patients were more likely to receive diabetes-specific preventive care, including diabetes-related office visits and testing for kidney disease.

Funding for this research was provided by Better Medicare Alliance.

To learn more about how policy affects outcomes, connect with us.

Webinar: Decoding the CY 2025 Advance Notice Join Avalere’s healthcare policy experts as they dissect the CY 2025 Medicare Advantage Advance Notice and discuss the future trajectory of MA in Part D and potential outcomes, headwinds, and tailwinds for health plans. Learn More
Watch the Recording
From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Quality Improvement
Please enter your email address to be notified when new Quality Improvement insights are published.

Back To Top